Stock Price Movement and Market Context
On 24 Nov 2025, Epigral’s share price touched an intraday low of Rs.1428, representing a 2.08% decline for the day and underperforming its sector by 0.78%. This new low price is notably below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum over multiple time frames.
In contrast, the broader market has shown resilience. The Sensex opened 88.12 points higher and was trading at 85,343.57, a 0.13% gain on the day. The index remains close to its 52-week high of 85,801.70, just 0.54% away, supported by mega-cap stocks and a bullish alignment of its 50-day and 200-day moving averages. The Sensex has also recorded a 2.56% gain over the past three weeks, highlighting a divergence between Epigral’s performance and the overall market trend.
Long-Term and Recent Performance Analysis
Over the last year, Epigral’s stock has shown a total return of -26.32%, contrasting sharply with the Sensex’s 7.85% gain during the same period. The stock’s 52-week high was Rs.2195.85, underscoring the extent of the decline to the current low.
Epigral’s long-term growth trajectory has been subdued, with operating profit exhibiting a compound annual rate of decline of 5.49% over the past five years. This trend is reflected in the company’s recent quarterly results, where operating profit to net sales ratio reached a low of 22.53%, signalling pressure on profitability margins.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Quarterly Financial Highlights
The company’s latest quarterly figures reveal a mixed picture. Interest expenses over the last six months stood at Rs.45.21 crores, reflecting a growth of 286.41%, which may indicate increased financing costs. Meanwhile, the quarterly profit after tax (PAT) was Rs.51.22 crores, showing a decline of 52.6% compared to the average of the previous four quarters. These figures highlight challenges in maintaining profitability in the near term.
Despite these pressures, Epigral maintains a strong management efficiency, with a return on capital employed (ROCE) of 23.19%, which is a positive indicator of how effectively the company utilises its capital base. The company’s debt servicing capability is also notable, with a low Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels relative to earnings.
Valuation and Comparative Metrics
Epigral’s valuation metrics show a fair positioning relative to its capital employed, with an enterprise value to capital employed ratio of 2.6. The stock is trading at a discount compared to the average historical valuations of its peers in the Specialty Chemicals sector. Over the past year, while the stock price has declined by 26.32%, the company’s profits have risen by 37.1%, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.5. This divergence between profit growth and stock price performance reflects a complex market assessment of the company’s prospects.
Epigral or something better? Our SwitchER feature analyzes this small-cap Specialty Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Shareholding and Sector Position
Epigral operates within the Specialty Chemicals industry, a sector characterised by cyclical demand and sensitivity to raw material costs. The company’s majority shareholding rests with promoters, providing a stable ownership structure. However, the stock’s performance relative to the BSE500 index has been below par over the last three years, one year, and three months, indicating persistent challenges in delivering returns in line with broader market benchmarks.
While the Sensex and many large-cap stocks have shown resilience and upward momentum, Epigral’s stock continues to face downward pressure, as reflected in its recent 52-week low and underperformance against sector peers.
Summary of Current Concerns
The key factors contributing to Epigral’s recent stock price decline include subdued long-term growth in operating profit, a significant rise in interest expenses, and a sharp fall in quarterly PAT. The stock’s position below all major moving averages further emphasises the prevailing negative momentum. Additionally, the company’s returns over the past year have lagged the broader market indices and sector averages.
Nevertheless, the company’s strong ROCE and manageable debt levels provide some stability amid these challenges. The valuation discount relative to peers also reflects the market’s cautious stance on the stock’s near-term outlook.
Conclusion
Epigral’s fall to a 52-week low of Rs.1428 marks a significant milestone in its recent share price trajectory. The stock’s underperformance relative to the Sensex and its sector peers highlights ongoing pressures within the company’s financial performance and market positioning. Investors and market watchers will note the divergence between profit growth and stock price movement, as well as the company’s solid capital efficiency and debt metrics. The broader market’s positive trend contrasts with Epigral’s current valuation and price levels, underscoring the differentiated performance within the Specialty Chemicals sector.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
